SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vineet Laboratories - Quaterly Results

12 Feb 2025 Evaluate
The Sales for the quarter ended December 2024 of Rs. 180.99 million declined by -44.56% from Rs. 326.47 millions.The Net Loss for the quarter ended December 2024 is Rs. -57.06 millions as compared to Net Loss of Rs. -20.65 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 further decreased to -41.03% as compared to -6.29% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 180.99 326.47 -44.56 609.19 1135.43 -46.35 1505.91 2122.93 -29.06
Other Income 0.33 0.12 175.00 6.06 0.52 1065.38 4.63 1.23 276.42
PBIDT -41.03 -6.29 552.31 -46.32 38.38 -220.69 76.63 77.82 -1.53
Interest 9.51 10.77 -11.70 30.78 30.61 0.56 47.81 33.80 41.45
PBDT -50.54 -17.06 196.25 -77.10 7.77 -1092.28 28.82 44.02 -34.53
Depreciation 6.19 6.26 -1.12 18.44 18.47 -0.16 25.19 23.73 6.15
PBT -56.73 -23.32 143.27 -95.54 -10.70 792.90 3.63 20.29 -82.11
TAX 0.33 -2.67 -112.36 1.12 -1.73 -164.74 -6.64 7.77 -185.46
Deferred Tax 0.33 0.25 32.00 1.12 0.14 700.00 -5.99 2.17 -376.04
PAT -57.06 -20.65 176.32 -96.66 -8.97 977.59 10.27 12.52 -17.97
Equity 92.19 92.19 0.00 92.19 92.19 0.00 92.19 92.19 0.00
PBIDTM(%) -22.67 -1.93 1076.61 -7.60 3.38 -324.94 5.09 3.67 38.82

Vineet Laboratories Share Price

32.75 -0.36 (-1.09%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×